Identification of KRAS(G12C) Mutations in Circulating Tumor DNA in Patients With Cancer

KRAS is the most mutated proto-oncogene that has been identified in cancer, and treatment of patients with KRAS mutations remains an arduous challenge. Recently, KRAS(G12C) mutation has attracted special interest because it is now considered potentially druggable with recently developed covalent sma...

Descripción completa

Detalles Bibliográficos
Autores principales: Thein, Kyaw Z., Biter, Amadeo B., Banks, Kimberly C., Duda, Andrew W., Saam, Jennifer, Roszik, Jason, Janku, Filip, Skoulidis, Ferdinandos, Heymach, John V., Kopetz, Scott, Meric-Bernstam, Funda, Hong, David S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2022
Materias:
Original Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9365336/
https://www.ncbi.nlm.nih.gov/pubmed/35862868
http://dx.doi.org/10.1200/PO.21.00547

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9365336/
https://www.ncbi.nlm.nih.gov/pubmed/35862868
http://dx.doi.org/10.1200/PO.21.00547

Ejemplares similares